Last reviewed · How we verify
standard-dose group VS high-dose group
At a glance
| Generic name | standard-dose group VS high-dose group |
|---|---|
| Sponsor | The First Affiliated Hospital of Anhui Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 (PHASE3)
- A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (PHASE2)
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (PHASE2)
- Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients (NA)
- Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock (PHASE4)
- Safety and Immunogenicity of ID vs IM Rabies Vaccine (PHASE2, PHASE3)
- Dose-escalation of Rectal Indomethacin for Preventing PEP (PHASE4)
- RCT: Suzetrigine vs Norco for Post-op Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: